Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 4Active not recruiting 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Liver Neoplasms 3Stomach Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Squamous Cell 2Urothelial Cancer 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Hepatocellular Carcinoma 1Solid Malignancies 1Seminoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Nonseminomatous germ cell tumor 1Non Small Cell Lung Cancer NSCLC 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Neoplasm Metastasis 1Microsatellite Instability 1Metastatic Malignant Female Reproductive System Neoplasm 1Mesothelioma, Malignant 1Lung Cancer Metastatic 1Immunotherapy 1Hydronephrosis 1

Interventions

Carboplatin 15durvalumab 14Etoposide 14pembrolizumab 9atezolizumab 9Cisplatin 9Topotecan 8Nivolumab 7Specimen Handling 6olaparib 4berzosertib 4Temozolomide 4Magnetic Resonance Spectroscopy 4AMG 757 4tremelimumab 3Radiotherapy 3Radiosurgery 3PM 01183 3Ipilimumab 3Docetaxel 3Biopsy 3niraparib 2lenvatinib 2cabozantinib 2Platinum 2Irinotecan 2Fulvestrant 2veliparib 1tislelizumab 1tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Small Cell Lung Carcinoma × tremelimumab × Clear all
NCT03043872 2026-04-22

CASPIAN

AstraZeneca

Phase 3 Active not recruiting
987 enrolled 42 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
25 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03703297 2025-11-21

ADRIATIC

AstraZeneca

Phase 3 Active not recruiting
730 enrolled 19 charts 1 FDA
Thoracic

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡